Background:

Iganidipine is a Ca2+ antagonist.

Iganidipine (0.03% solution) significantly increases optic nerve head (ONH) tissue blood velocity (NBONH) by 8 to 10% in treated eyes after a single administration (p<0.05) or by 18 to 35% after 7-, 14-, or 21-day twicedaily administration in rabbits (p<0.05). In monkeys, 0.03% and 0.1% Iganidipine significantly increases NBONH in treated eyes by 20 and 41% after 7-day (p<0.05) twice-daily administration, respectively[1].

[1]. Ishii K, et al. Iganidipine, a new water-soluble Ca2+ antagonist: ocular and periocular penetration after instillation. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1169-77.